Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 11, 2020
Reporting Period: Single event date (November 11, 2020)
Business Context: The Company is an emerging growth company incorporated in Nevada, with principal executive offices in La Jolla, California. Its common stock trades on The NASDAQ Stock Market LLC under the symbol "INMB".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K serves solely to transmit an investor presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial position or operations are reported in this document. The filing is procedural, intended to satisfy disclosure obligations regarding the distribution of an investor presentation.
Guidance, Outlook, and Risks
- Event: Filing of an investor presentation (Exhibit 99.1).
- Management Commentary: The Company explicitly states it makes no admission as to the materiality of the information contained in the presentation.
- Forward-Looking Statements: The information is summary in nature and intended to be considered in the context of other SEC filings and public announcements.
- Update Obligation: The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, though it may do so at management's discretion.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation) for specific operational or financial details not included in this summary.
- Verify the current status of the Company's emerging growth company election and any related accounting standard transitions.
- Check subsequent press releases or SEC filings for updates, as the Company has disclaimed an obligation to update the information in this specific report.
- Confirm the trading status of the "INMB" symbol on The NASDAQ Stock Market LLC.